1 February 2021 in Surgical Infections
Background: Infection is a major cause of morbidity and mortality among burn patients, and it is important to understand the progression of wound colonization to wound infection to systemic sepsis. Methods: After a review of the literature we describe the clinical characteristics of burn wound colonization, infection, and sepsis, and conclude with best practices to decrease these complications. Results: Burn wounds are initially sterile after the thermal insult but become colonized by gram-positive organisms and subsequently by gram-negative organisms. Some populations are especially susceptible to initial or subsequent colonization by drug-resistant organisms. An increase in fungal colonization has been observed because of the widespread use of topical antibiotic agents. Male gender, older age, lower extremity burn, scald burn, full-thickness burn, delay in treatment, and pre-existing diabetes place patients at increased risk of infection. These infections range from cellulitis that requires systemic antibiotic agents, to invasive burn wound infection that requires prompt treatment with antibiotic agents and excision. Fungal wound infections pose a special challenge and cause substantial morbidity. Infection that leads to systemic sepsis is difficult to define in burn patients because of the body's compensatory hypermetabolic response to the burn injury. Potential sources of sepsis include wound infections and common nosocomial infections. The American Burn Association Sepsis criteria, defined in 2007, has demonstrated poor specificity for identifying sepsis and septic shock. The best approach to decrease wound infections is prevention. Practices that have been beneficial include isolation rooms, handwashing, appropriate wound care, early excision and grafting, antibiotic stewardship, and nutritional support. Conclusions: A burn patient remains at a substantial risk of wound infection despite advances in care. A burn care provider must understand the natural progression of colonization to infection to sepsis, and the multidisciplinary approach to wound care to limit the morbidity and mortality from these infectious.
23 April 2020 in JCI Insight
BACKGROUND: Prehospital plasma improves survival in severely injured patients transported by air ambulance. We hypothesized that prehospital plasma would be associated with a reduction in immune imbalance and endothelial damage. METHODS: We sampled blood from 405 trauma patients enrolled in the Prehospital Air Medical Plasma (PAMPer) trial upon hospital admission (0 hours) and 24 hours post admission across 6 U.S. sites. We assayed samples for 21 inflammatory mediators and 7 markers associated with endothelial function and damage. We performed hierarchical clustering analysis (HCA) of these biomarkers of the immune response and endothelial injury. Regression analysis was used to control for differences across study and to assess any association with prehospital plasma resuscitation. RESULTS: HCA distinguished two patient clusters with different injury patterns and outcomes. Patients in cluster A had greater injury severity and incidence of blunt trauma, traumatic brain injury, and mortality. Cluster A patients that received prehospital plasma showed improved 30-day survival. Prehospital plasma did not improve survival in cluster B patients. In an adjusted analysis of the most seriously injured patients, prehospital plasma was associated with an increase in adiponectin, IL-1β, IL-17A, IL-23, and IL-17E upon admission, and a reduction in syndecan-1, TM, VEGF, IL-6, IP-10, MCP-1, and TNF-α, and an increase in IL-33, IL-21, IL-23, and IL-17E 24 hours later. CONCLUSION: Prehospital plasma may ameliorate immune dysfunction and the endotheliopathy of trauma. These effects of plasma may contribute to improved survival in injured patients. TRIAL REGISTRATION: NCT01818427. FUNDING: Department of Defense; National Institutes of Health, U.S. Army.
1 September 2009 in Journal of Trauma: Injury, Infection & Critical Care
Introduction: Nonoperative management (NOM) of blunt splenic injury has become the preferred treatment for hemodynamically stable patients. The application of splenic artery embolization (SAE) in NOM has been controversial. We hypothesized that incorporation of initial use of SAE into a practice protocol for patients at high risk for NOM failure (contrast extravasation or pseudoaneurysm on computed tomography, grade 3 injury with large hemoperitoneum, grade 4 injuries) would improve patient outcomes. Methods: A retrospective analysis of three continuums of practice was performed: group I (January 1991–June 1998), SAE not part of routine NOM; group II (July 1998–December 2001), introduction and discretionary use of SAE; and group III (January 2002–June 2007), standardized use of initial SAE for patients considered at high risk of nonoperative failure. The primary outcome measure was the success of NOM. Failure of NOM was defined as the need for abdominal operation. Secondary outcomes were mortality, length of stay, and splenic salvage. Results: Over 16 years, 815 patients with blunt splenic injury were treated at our level 1 trauma center. There were 222 patients in group I, 195 in group II, and 398 in group III. There was an increase in the use of SAE over time with a significant improvement in the utilization of NOM (61% in group I; 82% in group II; 88% in group III; p < 0.05). This was associated with an increase in successful NOM (77%, group I; 94%, group II; 97%, group III; p < 0.0001 group I vs. group II and III). Mortality, length of stay, and splenic salvage were similar in groups II and III but significantly improved when compared with group I. Conclusions: The increased use of initial SAE in high-risk patients expanded the successful use of NOM but was not associated with other incremental improvements.
1 February 2021 in Surgical Infections
Background: Severe burn injury results in substantial damage to the skin, inhibiting its ability to perform as the primary barrier to infection. Additionally, severe burn injury can lead to critical illness and extensive time in the intensive care unit (ICU). These two factors work to increase the risk of sepsis in the burn patient compared with other hospitalized patients. The increased risk of sepsis is compounded by the difficulty of diagnosing sepsis in severely burned patients because the pathophysiology of large burns mimics sepsis, leading to possible delay in diagnosis and initiation of treatment. Methods: A literature review was performed to discuss and review the diagnostic difficulties and criteria used to identify patients with sepsis. Additionally, the most current management of sepsis was reviewed and described in caring for burn patients with sepsis. Results: The incidence of sepsis in patients with more than 20% total body surface area (TBSA) burns is between 3% and 30% and is the most common cause of death in the burn patient, with pneumonia being the most common etiology. Several different diagnostic criteria for diagnosing sepsis in burn patients exist, however, none of these criteria have proven to be superior to clinical diagnosis by an experienced burn surgeon. As with sepsis in other patient populations, prompt diagnosis, initiation of antibiotic agents, and source control remain the standard management of sepsis in the burn patient. Conclusions: Because of the loss of the primary infection barrier function of the skin after a substantial burn injury, this patient population is at increased risk for sepsis. Because of the pathophysiology of burn injuries, diagnosing sepsis in the burn population remains challenging. Understanding the most common etiologies of sepsis in burn patients may help with more expedient diagnosis and initiation of treatment.
1 February 2007 in Surgical Infections
Ventilator-associated pneumonia (VAP) is a frequent complication during recovery of severely traumatized patients. The primary objective of this study was to determine if prophylactic administration of aerosolized ceftazidime reduced the incidence of VAP in high-risk injured patients without altering the incidence of other infectious complications. This was a single-institution double-blind, randomized trial that compared a seven-day course of aerosolized ceftazidime with placebo. Intubated high-risk patients admitted to the trauma intensive care unit at a large regional trauma center between February 2003 and September 2005 were eligible for enrollment. The main outcome evaluated was the incidence of VAP at two weeks and 30 days. The incidences of multi-drug-resistant infections and other infectious complications were secondary outcomes. A total of 105 patients were randomized, resulting in 52 patients in the placebo arm and 53 patients in the ceftazidime arm. There was no statistical difference between the groups with regard to demographic data, injury severity, calculated risk of VAP, or the number of doses received. In the intention-to-treat analysis, the incidence of VAP at two weeks was 24/52 (46%) in the placebo group and 21/53 (40%) in the ceftazidime group. The number of patients with VAP at 30 days was 26/52 (50%) in the placebo group and 26/53 (49%) in the ceftazidime group. There was no statistical difference in the development of multi-drug-resistant VAP or other infectious complications in the two groups. The use of aerosolized ceftazidime did not reduce the rate of VAP in high-risk patients admitted after traumatic injury, but neither did it increase the incidence of other infectious complications. Routine use of prophylactic aerosolized ceftazidime to prevent VAP in trauma patients cannot be recommended.
1 April 2015 in Journal of Trauma and Acute Care Surgery
BACKGROUND The Northern Ohio Trauma System (NOTS) was established to improve outcomes of trauma patients across the region. We hypothesized that mortality in patients with traumatic brain injury (TBI) would improve after regionalization. METHODS All patients older than 14 years with a TBI were identified from NOTS, a regional trauma system consisting of two large health care systems and regional emergency medical services providers. Data from 2008 through 2012 were analyzed before and after NOTS formation in 2010. Multivariate logistic regression analysis was performed to evaluate independent predictors of survival. RESULTS A total of 11,220 patients were identified with TBI in the NOTS database, 4,507 (40%) before NOTS and 6,713 (60%) after NOTS formation. Admissions to the regional Level 1 center post-NOTS formation increased from 36% to 46% (p < 0.0001). Injury Severity Scores (ISSs) and Abbreviated Injury Scale (AIS) scores were similar between periods. The mortality rate decreased from 6.2% to 4.9% (p = 0.005) among all TBIs and from 19% to 14% (p < 0.0001) in TBIs with a head AIS score of 3 or greater (n = 3,538). Craniotomy procedures increased from 1.8% to 2.7% (p = 0.003) overall and from 5.9% to 8.1% (p = 0.02) in TBIs with head AIS score of 3 or greater. Logistic regression analysis demonstrated an independent effect on survival for post-NOTS period in all patients (odds ratio, 0.76; 95% confidence interval, 0.62–0.94; C statistic = 0.96) and in TBIs with head AIS score of 3 or greater (odds ratio, 0.72; 95% confidence interval, 0.58–0.89; C statistic = 0.86). CONCLUSION Regionalization of trauma care across hospital systems is associated with a reduced mortality rate for patients with TBI, particularly for patients with a head AIS score of 3 or greater. Mortality decreased by 24% for all TBIs and by 28% for severe TBIs. These findings support regionalization of trauma care with collaboration and consolidation of care across health care systems. LEVEL OF EVIDENCE Therapeutic/care management, level IV; epidemiologic study, level III.